Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE <b>Background:</b> The PI3K/AKT/mTOR pathway is an important oncogenic driver in triple-negative breast cancer (TNBC). 29675095 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE <b>Conclusion:</b> We demonstrated that DFO could upregulate expression of TfR1 and DMT1 , which enhanced iron uptake via activating IL-6/PI3K/AKT signaling pathway in aggressive TNBCs. 31213851 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. 27893038 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE PI3K/mTOR inhibitors had an additive growth inhibitory effect when combined with genetic or pharmacological AR targeting in AR + TNBC cells. 25103565 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 GeneticVariation disease BEFREE Activation of PI3K signaling is frequently observed in triple-negative breast cancer (TNBC), yet PI3K inhibitors have shown limited clinical activity. 29472518 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE AKT3 is an oncogene of known relevance in breast cancer, and as a proof of principle we show that inhibition of phosphoinositide 3-kinase (PI3K) activity, a protein upstream of AKT3, suppressed proliferation in TNBC preneoplastic cells. 28160548 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). 31703728 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Applying this dataset to triple-negative breast cancer, we report clinically actionable interactions with the MYC oncogene, including resistance to AKT-PI3K pathway inhibitors and an unexpected sensitivity to dasatinib through LYN inhibition in a synthetic lethal manner, providing new drug and biomarker pairs for clinical investigation. 25501949 2015
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE As EGFR/PI3K/Akt pathway proteins are frequently altered in TNBC, we have studied the gene expression of key proteins of this pathway. 28766167 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 GeneticVariation disease BEFREE CF33 was effective <i>in vitro</i> with potent cytotoxicity and efficient intracellular replication observed in TNBC lines with phosphatidylinositol 3-kinase (PI3K)/Akt pathway mutations that resulted in endogenous phospho-Akt (p-Akt) activity (BT549, Hs578T, and MDA-MB-468). 29988465 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Consequently, targeted therapies based on the interaction of PI3K inhibition with BRCA1 mutations or HR deficiency in TNBC may be a promising strategy for the treatment of patients with TNBC. 31804921 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. 24236784 2013
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer. 29228721 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Different targeted therapies may be necessary for TNBC that involves activation of PI3K/AKT or MAPK pathways. 25009009 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Due to the absence of molecular markers for TNBC his treatment options remains limited, without proven targeted therapies, which emphasize the need for discovering molecular markers that could be targeted for patient treatment, An important number of TNBC cases harbor aberrations in the phosphoinositide 3-kinase (PI3K) pathway, leading to constitutive activation of the downstream signaling pathway. 30227836 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Expression analysis of the panel of TNBC cell lines indicates that the expression levels of IGF2BP3 can be used as a potential predictor for sensitivity to the PI3K/IGF1R inhibitor combination. 27196766 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Further study of underlying mechanisms demonstrated that DANCR bound with RXRA and increased its serine 49/78 phosphorylation via GSK3β, resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis. 30518934 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE GDC-0941 is a pan-PI3K inhibitor that activates the WNT/beta-catenin pathway in TNBC cells through stimulation of WNT secretion. 25857298 2015
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Here, we provide new evidence of the effects of exercise on TNBC prevention, control, and outcomes, based on the inhibition of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB also known as Akt)/mammalian target of rapamycin (mTOR) (PI3K-Akt-mTOR) signaling. 30363988 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In accordance with increased PI3K signaling following long-term CDC25 inhibition, CDC25 and PI3K inhibitors effectively synergized to suppress TNBC growth both in vitro and in xenotransplantation models. 29617654 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In the present study, we aimed to investigate, the effect of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway dual inhibitor, NVP-BEZ235 and Caffeic acid phenyl ester (CAPE) on TNBC cell line (MDA-MB-231), stimulated with TGF-β1 for 14days in vitro. 28528184 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC. 29924958 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In this study, we compared the effect of eribulin on the PI3K/AKT/mTOR pathway with other microtubule-targeting agents in TNBC. 31480338 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In vivo in a mouse model of BRCA1-linked triple-negative breast cancer (K14-Cre BRCA1(f/f)p53(f/f)), the PI3K inhibitor BKM120 led to a precipitous drop in DNA synthesis within 8 h of drug treatment, whereas DNA synthesis in normal tissues was less affected. 27402769 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Inhibition of the PI3K/mTOR pathway in TNBC cell lines decreased notably the expression of the AR. 24779793 2014